Compare Natera Inc. Common Stock (NTRA) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while GraniteShares 2x Long NVDA Daily ETF trades at $33.58 (market cap $3.52B). The key difference: Natera Inc. Common Stock is far larger — about 16.2× GraniteShares 2x Long NVDA Daily ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and GraniteShares 2x Long NVDA Daily ETF for 15 Days on average.
| NTRA | NVDL | |
|---|---|---|
Market Cap | $57.03B | $3.52B |
Volume | 1,131,157 | 6,205,788 |
Sector | Health | Leveraged / Inverse |
52-Week High | $425.64 | $43.02 |
52-Week Low | $179.42 | $21.76 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.58 with a 1.81% daily gain. Technical indicators show a bullish overall signal with mixed moving averages and neutral oscillators. The ETF tracks Nvidia's performance with 2x daily leverage, though recent articles highlight it underperformed NVDA's 22.21% one-year return with only 17.21%. Recent news focuses on Nvidia's strong earnings and AI leadership driving optimism.
The outlook remains tied to Nvidia's AI dominance and earnings momentum, offering leveraged exposure to chip sector growth. Key risks include leverage decay, tracking error, and Nvidia's high valuation sensitivity. Investors should weigh the ETF's daily reset mechanism against long-term holding costs amid volatile tech markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
